Sugi Predict

Sugi Predict / Compounds / SCHEMBL9955669

SCHEMBL9955669

SCHEMBL9955669

Cc1ccc(-c2cn3nc(-c4ccccc4Cl)ccc3n2)cc1NC(=O)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ GLA P06280 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ MAPT P10636 3/20 0.42
▸ CSNK1D P48730 8/20 0.41
▸ CSNK1E P49674 8/20 0.41
▸ MITF O75030 1/20 0.41
▸ KLF5 Q13887 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ TP53 P04637 2/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ TTK P33981 1/20 0.38
▸ RIPK1 Q13546 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9956705 0.91 CSNK1D (0.42) MEN1KMT2AMAPTCSNK1DCSNK1E
SCHEMBL9956729 0.89 MAPT (0.41) KDM4EALDH1A1HPGDMAPTCSNK1D
SCHEMBL9956830 0.89 RIPK1 (0.43) KDM4EALDH1A1HPGDMAPTCSNK1D
SCHEMBL9956160 0.89 CSNK1D (0.45) CSNK1DCSNK1ELMNATP53RXFP1
SCHEMBL9956360 0.88 RXFP1 (0.45) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL9955681 0.88 MAPT (0.40) KDM4EALDH1A1MAPTCSNK1DCSNK1E
SCHEMBL9955856 0.88 CSNK1D (0.43) MAPTCSNK1DCSNK1ERIPK1
SCHEMBL9956448 0.87 RXFP1 (0.46) MAPTCSNK1DCSNK1ETP53RXFP1
SCHEMBL9955573 0.86 CSNK1D (0.40) ALDH1A1MAPTCSNK1DCSNK1ETTK
SCHEMBL9956892 0.86 CSNK1D (0.45) KDM4EALDH1A1HPGDGLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2635578-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES Hengrui (USA) Ltd. (US) 2013-09-11 — — EP claimed
US-20120178751-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES HENGRUI (USA), LTD. 2012-07-12 — — US claimed
WO-2012088411-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES PAMLICO PHARMACEUTICAL INC. (US) 2012-06-28 — — WO claimed
EP-2635578-B1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES HENGRUI USA LTD (US) 2015-12-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178751-A1 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES PRXL2A, CDK2, CCNA2 KDM4E 2693/4885ALDH1A1 334/4885HPGD 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.